OXFORD, UK, September 4th, 2015
PharmaVentures is pleased to announce that it acted as advisor to Douglas Pharmaceuticals, New Zealand's largest pharmaceutical manufacturer, in acquiring from Auckland-based Vital Foods their Phloe® product line in New Zealand for an undisclosed sum. The deal, completed on 1st September, includes an option for additional territories.
The sale of the Phloe® product line to Douglas Pharmaceuticals allows for the growth of Phloe® in New Zealand and enables Vital Foods to focus more effectively on the international market for Phloe® products.
Phloe® Bowel Health contains Zyactinase®, a proprietary kiwifruit extract with a unique mode of action derived from naturally occurring prebiotics, enzymes and fibre that aids regular and efficient bowel function.
Aki von Roy, Associate Director Asia-Pacific, PharmaVentures, said: "We are delighted to support Douglas Pharmaceuticals in its plans for growth both in New Zealand and globally".
Fintan Walton, Chief Executive, PharmaVentures, added: "This latest deal reflects the growing number of global deals that we have achieved in recent years"
For the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.